Kimberly Levinson
Advanced in Ovarian Carcinosarcoma

Dr. Kimberly Levinson

Obstetrics and Gynecology | Oncology
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 6, Floor 6, 
Baltimore, MD 
Offers Telehealth

Advanced in Ovarian Carcinosarcoma
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 6, Floor 6, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kimberly Levinson, M.D., is an associate professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Her areas of clinical expertise include minimally invasive surgery with both robotic and single incision laparoscopy, ovarian cancer debulking, cervical cancer and dysplasia. Dr. Levinson received her undergraduate degree from Tufts University. She earned her M.D. from the Johns Hopkins University School of Medicine and her M.P.H. from the Johns Hopkins Bloomberg School of Public Health. She completed her medical residency at the Johns Hopkins University School of Medicine and performed a clinical fellowship in gynecologic oncology at Cleveland Clinic. Dr. Levinson has also completed international research at Preventive Oncology International in Peru and the School for International Training in Chile. Dr. Levinson joined the Johns Hopkins faculty in 2014. Her research interests include health care disparities in gynecologic tumors, cervical cancer prevention and treatment, and surgical innovation. She has published numerous manuscripts in gynecologic oncology involving these and other various research topics. Dr. Levinson is currently a principal investigator in the Specialized Program of Research Excellence (SPORE) in Cervical Cancer. In addition, she has a strong commitment to education, and she is the assistant director of the Johns Hopkins residency program and the associate director of the Gynecologic Oncology fellowship. Dr. Levinson is a member of the American College of Obstetricians and Gynecologists, the Society of Gynecologic Oncology, and the American Medical Association. Dr. Levinson was recognized with a Robert B. Hunt Award for Best Paper Published in the Journal of Minimally Invasive Gynecology in 2014.

Dr. Levinson is rated as an Advanced provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Endometrial Cancer, Testicular Yolk Sac Tumor, Ovarian Cancer, Hysterectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Johns Hopkins Bloomberg School Of Public Health, MPH, 2006
Residency
Johns Hopkins University School of Medicine, Obstetrics and Gynecology, 2011
Specialties
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in MD
Board Certifications
American Board Of Obstetrics And Gynecology
Fellowships
Cleveland Clinic, Gynecologic Oncology, 2014
Hospital Affiliations
Greater Baltimore Medical Center
The Johns Hopkins Hospital
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 6, Floor 6, Baltimore, MD 21287
Call: 410-955-8240

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Carboplatin, Paclitaxel
Study Phase: Phase 3
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Enrollment Status: Completed
Publish Date: November 16, 2021
Intervention Type: Procedure, Drug, Other
Study Phase: Early Phase 1
A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Enrollment Status: Completed
Publish Date: April 28, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

64 Total Publications

Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.
Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.
Journal: JCO global oncology
Published: October 08, 2025
View All 64 Publications
Similar Doctors
Rebecca L. Stone
Distinguished in Ovarian Carcinosarcoma
Dr. Rebecca L. Stone
Oncology | Obstetrics and Gynecology
Distinguished in Ovarian Carcinosarcoma
Dr. Rebecca L. Stone
Oncology | Obstetrics and Gynecology

Johns Hopkins Outpatient Center

Baltimore, MD 
 (1.2 miles away)
410-955-8240
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Rebecca Stone is an associate professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Her area of clinical expertise is gynecologic cancers, including cervical, uterine, vulvar and ovarian cancer, as well as gestational trophoblastic disease. Dr. Stone is a highly skilled surgeon with expertise in laparoscopic and robotic surgery for gynecologic tumors. She also serves as director of the Gynecology Enhanced Recovery after Surgery initiative, an innovative, multidisciplinary program that improves recovery and healing time after major abdominal surgery, as well as minimizes health care costs for patients. Dr. Stone received her undergraduate degree in biology from the University of Virginia. She earned her medical degree from the University of Virginia School of Medicine, where she subsequently completed her residency in obstetrics and gynecology. Dr. Stone performed a four-year gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. She also earned a master’s degree in cancer biology from the University of Texas in 2010. Prior to joining Johns Hopkins, Dr. Stone was an assistant professor at the University of Arkansas for Medical Sciences, where she was one of five gynecologic oncologists serving the entire state. Dr. Stone is internationally recognized for her research pertaining to early diagnosis and treatment of ovarian cancer. She is widely published in the field of gynecologic oncology, with first-author papers in the New England Journal of Medicine and Lancet Oncology, as well as over 40 co-authored manuscripts in peer-reviewed medical journals. She was honored with an award for one of the most influential papers published in the field of obstetrics and gynecology in 2012 and with an Ovarian Cancer Research Fund Grant for “Unplugging Ovarian Cancer from the Power of Platelets.” Dr. Stone strongly believes in a multidisciplinary team approach to gynecologic cancer care. She seeks to provide women with the most advanced and personalized treatment plans while best preserving quality of life. She enjoys working with community providers so that patients are comforted by receiving care close to home. Dr. Stone is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

Amanda N. Fader
Distinguished in Ovarian Carcinosarcoma
Dr. Amanda N. Fader
Obstetrics and Gynecology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Amanda N. Fader
Obstetrics and Gynecology | Oncology

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville

Lutherville, MD 
 (10.1 miles away)
443-997-0400
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Dr. Amanda Nickles Fader is a professor in the Johns Hopkins Hospital Department of Gynecology and Obstetrics and the Sidney Kimmel Cancer Center. She is the former fellowship director and division director of the Johns Hopkins Kelly Gynecologic Oncology Service and currently is Vice Chair of Gynecologic Surgical Operations and the Director of the Center for Rare Gynecologic Cancers. Additionally, she serves as the 2024-2025 President of the Society of Gynecologic Oncology. Dr. Fader received her undergraduate degree with highest distinction in music (violin performance) and pre-medicine from the University of Virginia. She earned her medical degree from the Medical College of Virginia, and completed her residency in obstetrics and gynecology at the Magee-Women’s Hospital of UPMC in Pittsburgh. Dr. Fader then underwent gynecologic oncology fellowship training at the Cleveland Clinic. She has co-authored more than 230 publications in peer-reviewed medical journals and is recognized as an expert in rare gynecologic tumors, clinical trials and quality and safety in surgery. She has a special interest in uterine serous carcinoma and low-grade serous carcinoma of the ovary and currently serves as the PI or co-PI of three international NRG Oncology clinical trials. Dr. Fader serves as a national board examiner in gynecologic oncology for the American Board of Obstetrics and Gynecology and Associate Editor of the Gynecologic Oncology journal is a member of the Rare Tumor and Uterine Corpus Committees of the NRG/Gynecologic Oncology Group. She is also co-founder of the Society of Gynecologic Oncology BRIDGES Program, a two-year longitudinal clinical trials and career development program for early-career oncologists. She has been the recipient of several research grants and awards for her research, including the Society of Gynecologic Oncology Innovations Award, the Best AAGL Paper in Minimally Invasive Gynecologic Oncology Surgery, a Department of Defense Ovarian Cancer Clinical Trials Academy Leadership Award, and National Cancer Institute Cervical SPORE grant. Dr. Fader is consistently recognized for clinical excellence on lists such as Baltimore magazine’s Top Docs and Castle Connolly’s Top Doctors, and is a recipient of the Top 10 Docs, Compassionate Doctors and Patient Choice Awards from Vitals.com. She has particular expertise with the surgical and medical management of uterine (endometrial), ovarian, cervical and vulvar cancers, as well as the treatment of women who are at high risk for developing a gynecologic malignancy. She has a special interest in caring for patients throughout the entire spectrum of their lives: from preventive oncology — minimizing key risk factors that can lead to gynecologic cancers — to survivorship initiatives addressing all aspects of recovery, including emotional well-being, sexual health and clinical follow-up. Dr. Fader is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ovarian Cancer, Bladder Reconstruction, and Hernia Surgery.

Stephanie Gaillard
Distinguished in Ovarian Carcinosarcoma
Dr. Stephanie Gaillard
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Stephanie Gaillard
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 10th FL, Viragh BLDG 10th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English, French
See accepted insurances
Offers Telehealth

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies. Dr. Gaillard is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Tissue Biopsy, and Salpingo-Oophorectomy.

VIEW MORE OVARIAN CARCINOSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levinson's expertise for a condition
ConditionClose
    • Distinguished
    • Endometrial Cancer
      Dr. Levinson is
      Distinguished
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Ovarian Cancer
      Dr. Levinson is
      Distinguished
      . Learn about Ovarian Cancer.
      See more Ovarian Cancer experts
    • Testicular Yolk Sac Tumor
      Dr. Levinson is
      Distinguished
      . Learn about Testicular Yolk Sac Tumor.
      See more Testicular Yolk Sac Tumor experts
    • Advanced
    • Cervical Cancer
      Dr. Levinson is
      Advanced
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Cervical Dysplasia
      Dr. Levinson is
      Advanced
      . Learn about Cervical Dysplasia.
      See more Cervical Dysplasia experts
    • Endometrial Stromal Sarcoma
      Dr. Levinson is
      Advanced
      . Learn about Endometrial Stromal Sarcoma.
      See more Endometrial Stromal Sarcoma experts
    • Endometritis
      Dr. Levinson is
      Advanced
      . Learn about Endometritis.
      See more Endometritis experts
    • Malignant Mixed Mullerian Tumor
      Dr. Levinson is
      Advanced
      . Learn about Malignant Mixed Mullerian Tumor.
      See more Malignant Mixed Mullerian Tumor experts
    • Ovarian Carcinosarcoma
      Dr. Levinson is
      Advanced
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    View All 9 Advanced Conditions
    • Experienced
    • Adenomyosis
      Dr. Levinson is
      Experienced
      . Learn about Adenomyosis.
      See more Adenomyosis experts
    • Adult Soft Tissue Sarcoma
      Dr. Levinson is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Levinson is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Angiomyoma
      Dr. Levinson is
      Experienced
      . Learn about Angiomyoma.
      See more Angiomyoma experts
    • BRCA Positive Breast Cancer
      Dr. Levinson is
      Experienced
      . Learn about BRCA Positive Breast Cancer.
      See more BRCA Positive Breast Cancer experts
    • Cervical Polyps
      Dr. Levinson is
      Experienced
      . Learn about Cervical Polyps.
      See more Cervical Polyps experts
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.